Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 14;72(6):1523–1539. doi: 10.1007/s00262-022-03348-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PMC Copyright notice

Fig. 5 — Tumour bearing experiment in C57BL/6 mice. a Experimental scheme in which C57BL/6 mice were used to establish animal models. The experiment was divided into four groups: the control group (SCC7), experimental group (SCC7 + P. gingivalis), low-dose treatment group (SCC7 + P. gingivalis + 0.05 nM SCH527123), and high-dose treatment group (SCC7 + P. gingivalis + 0.20 nM SCH527123). The treatment group was injected with different doses of SCH527123 at the site of tumour cell inoculation at 4, 8, 12 and 16 days. Mice were sacrificed at 20 days. b In the control group, the tumour volume of mice killed on day 20 was less than that of mice in other three groups; in the experimental group, the tumour volume increased significantly compared with the control group, and continued to increase with the extension of time; when SCH527123 was used for treatment, it was found that the tumour volume in the low-dose treatment group was less than that in the experimental group. Similarly, compared with that in the experimental group, the tumour volume in the high-dose treatment group also decreased. Comparing the high-dose treatment group with the low-dose treatment group, it was found that the tumour inhibition was more obvious in the former. c. The tumour-bearing mouse model samples were assessed by HE staining and IHC. The IHC results showed that the expression of P. gingivalis was negative in the control group (SCC7) and positive in the experimental group (SCC7 + P. gingivalis). d. IF showed that CXCL2 and TANs were both expressed in the control group, and the levels of CXCL2 and TANs in the experimental group were higher than those in the control group. The levels of CXCL2 and TANs in the low-dose treatment group were lower than those in the experimental group. In the high-dose treatment group, the levels of CXCL2 and TANs were significantly lower than those in the low-dose treatment group. (*p < 0.05, **p < 0.01, and ***p < 0.001; one‐way analysis of variance).